Pharmaceutical company Amneal Pharmaceuticals Inc (Nasdaq: AMRX) announced on Tuesday that it has introduced PEMRYDI RTU, the inaugural ready-to-use version of pemetrexed for injection, offering convenience by eliminating reconstitution, dilution, or refrigeration requirements. This novel presentation aims to ease administration for patients.

PEMRYDI RTU received a unique J-Code from CMS for streamlined reimbursement. Available in 100mg/10mL and 500mg/50mL vial sizes, it targets metastatic non-squamous non-small cell lung cancer and malignant pleural mesothelioma in certain patient groups.

With US annual sales for pemetrexed reaching USD287m, according to IQVIA, Amneal plans to introduce two to three branded oncology 505(b)(2) products annually, marking PEMRYDI RTU® as the first of 2024.

Amneal is headquartered in Bridgewater, NJ and is known for its diverse portfolio of over 270 pharmaceutical products. The company focuses on expanding its generics segment across various therapeutic areas and is growing its specialty segment with a focus on central nervous system and endocrine disorders. Through its AvKARE segment, Amneal serves federal government, retail and institutional markets.